GERMANTOWN, Md., Feb. 2 Sensors for Medicine and Science, Inc., a clinical-stage, medical device company pioneering breakthrough technology that could dramatically improve glucose monitoring for people with diabetes, today announced the appointment of Dr. Paul Strumph as the company's Chief Medical Officer.
Dr. Strumph was most recently Vice President and Chief Medical Officer of the Juvenile Diabetes Research Foundation. At JDRF, his responsibilities included overseeing the clinical research portfolio and providing direction on clinical programs for JDRF's therapeutic areas, and providing guidance to JDRF on regulatory policy and therapeutic delivery issues, such as reimbursement and provider acceptance. He was also a member of the four-person Research Senior Management Team that set Research Strategy, and validated Program Area strategies and execution.
Prior to JDRF, Dr. Strumph held leadership positions in Clinical and Medical Affairs with Bristol-Myers Squibb & Co., Merck KGaA and GlaxoSmithKline, including clinical development of products in the therapeutic areas of diabetes, obesity and cardiovascular disease. This experience included advancing therapeutic compounds through Phase I - IV clinical studies.
Prior to entering industry, Dr. Strumph was a practicing endocrinologist and Clinical Assistant Professor at the UNC Department of Medicine. He received his medical degree with distinction in research, from the University of Rochester School of Medicine and Dentistry and is a diplomate of boards in Internal Medicine, Endocrinology, Diabetes & Metabolism, Pediatrics, and Pediatric Endocrinology.
"I am delighted to join Sensors for Medicine and Science and contribute to the development of this groundbreaking technology," said Dr. Strumph. "A long-term, continuous monitor that is sufficiently accurate to replace regular finger stick testing and does not require frequent calibration would be a major technical and clinical accomplishment. Successful clinical development and commercialization of the Company's unique implanted glucose monitor could significantly improve the lives of people with diabetes."
"Paul is a great addition to our management team," said Marc Schneebaum, President & CEO of Sensors for Medicine and Science. "His distinguished reputation in the adult and pediatric diabetes communities and his extensive clinical and regulatory experience at all stages will be a perfect complement to our scientific team as we advance our long-term, implanted glucose monitor through clinical development and to commercialization. Moreover, his hands-on experience with glucose monitoring and insulin delivery technology should help us shape the product for optimal use by both people with diabetes and their physicians."
Sensors for Medicine and Science's lead product is a long-term, implanted continuous glucose monitor* based on its unique and proprietary sensor technology. This product includes a miniaturized sensor and an external reader. The sensor is inductively powered and remotely interrogated, so there is no battery on-board and no wires connecting the implanted sensor to the external reader. As a result, after implantation, the sensor functions noninvasively, painlessly, automatically, and continuously. Distinctive features include:
The Company plans to continue pilot clinical studies during 2010, and to initiate a pivotal clinical study in 2011.
About Sensors for Medicine and Science, Inc.
Sensors for Medicine and Science, Inc. is pioneering breakthrough technology that could dramatically improve glucose monitoring for people with diabetes. The Company believes that its long-term, continuous glucose monitor technology has the potential to replace regular finger stick monitoring.
Sensors for Medicine and Science, Inc. has also developed oxygen sensor technology, with potential applications in areas such as metabolic monitoring (weight management), respiratory and cardiac disease. In addition, the Company sells its oxygen sensors as a component to original equipment manufacturers.
* NOTE: Sensors for Medicine and Science, Inc.'s glucose monitor is not available for sale and has not been approved by the U.S. Food and Drug Administration.
For more information about Sensors for Medicine and Science, Inc., please visit http://www.s4ms.com.
-- The sensor is designed to deliver accuracy that the Company believes could enable the product to replace regular finger stick monitoring. -- The sensor is designed to deliver accurate results even when glucose levels are low, and when glucose levels are changing rapidly. Accurate performance in these two situations is crucial to people with diabetes, and have proved to be particular challenges for competing devices. -- The Company is targeting an implant period of up to one year, along with extended stability of calibration.
SOURCE Sensors for Medicine and Science, Inc.